“In 2026, we have aligned our organization across three core therapeutic areas to ensure we have broader reach to patients who may benefit from our medicines while building a flexible infrastructure to add new programs as needed. Importantly, we’ve begun the year in a strong financial position, enabling us to pursue our ambitious goals.”